Cargando…

PB2230: THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?

Detalles Bibliográficos
Autor principal:	Cuadrado, Isabel Montero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429715/ http://dx.doi.org/10.1097/01.HS9.0000975664.43352.07

Ejemplares similares

PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
por: Kaynak, Emine, et al.
Publicado: (2023)

PB2056: MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?
por: Montero, M. I.
Publicado: (2022)

PB2230: EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT
por: Karimi, M., et al.
Publicado: (2022)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

PB2055: A RARE CASE OF HIGH-RISK HEREDITARY THROMBOPHILIA COMBINED WITH PRIMARY MYELOFIBROSIS
por: Khoduleva, S., et al.
Publicado: (2022)

PB2166: PRIMARY MYELOFIBROSIS: SERUM LACTATE DEHYDROGENASE AS A PREDICTOR OF EARLY LEUKEMIC PROGRESSION
por: Moura, Pedro, et al.
Publicado: (2023)

PB2039: CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY
por: Huang, J., et al.
Publicado: (2022)

PB2228: WHAT IS THE UTILITY OF THE MYSEC-PM ON SECONDARY MYELOFIBROSIS RISK STRATIFICATION IN A REAL LIFE SETTING?
por: Moura, Pedro, et al.
Publicado: (2023)

PB2052: CLINICOPATHOLOGIC VARIABLES AFFECTING DISEASE OUTCOME IN PRIMARY MYELOFIBROSIS. A SINGLE CENTER EXPERIENCE.
por: Elkourashy, S., et al.
Publicado: (2022)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

PB2231: AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE
por: Riazat-Kesh, Yosef Joseph Rene Amel, et al.
Publicado: (2023)

PB2196: CLINICAL IMPACT OF NUTRITIONAL STATUS AND NUTRITIONAL MONITORING IN PRIMARY MYELOFIBROSIS PATIENTS: PRELIMINARY RESULTS OF NUTRIMY STUDY
por: Malchiodi, Margherita, et al.
Publicado: (2023)

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
por: Palacio, Melisa, et al.
Publicado: (2023)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
por: Chen, C., et al.
Publicado: (2022)

PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS
por: Junker, Sophia, et al.
Publicado: (2023)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB2251: SOMETIMES IT’S ZEBRAS: SUCCESSFUL TREATMENT OF ERYTHROPOIETIC PROTOPORPHYRIA POST PRIMARY MYELOFIBROSIS WITH GIVOSIRAN - A CASE REPORT
por: Catana, Alina, et al.
Publicado: (2023)

PB2238: ATYPICAL CHRONIC MYELOID LEUKEMIA. CLINICAL AND MOLECULAR FEATURES. A SINGLE CENTER EXPERIENCE.
por: Martínez, Javier Alberto Rojas, et al.
Publicado: (2023)

PB2051: PRIMARY MYELOFIBROSIS IN YOUNG PATIENTS ≤50 YEARS: CLINICOPATHOLOGICAL CHARACTERISTICS, GENETIC LANDSCAPE AND DISEASE OUTCOME. A SINGLE CENTER EXPERIENCE
por: Elkourashy, S., et al.
Publicado: (2022)

PB2177: MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY.
por: Bonuomo, Valentina, et al.
Publicado: (2023)

PB2057: REAL -WORLD OVERALL SURVIVAL OF MYELOFIBROSIS PATIENTS ON RUXOLITINIB – A 6 YEAR ANALYSIS IN ALBANIAN POPULATION
por: Perolla, A., et al.
Publicado: (2022)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
por: Mascarenhas, John, et al.
Publicado: (2023)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
por: Masarova, Lucia, et al.
Publicado: (2023)

PB2184: IMPACT OF TRANSFUSION BURDEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSIS OF SIMPLIFY-1 AND -2
por: Mesa, Ruben, et al.
Publicado: (2023)

PB2374: DIFFERENCES IN MUTATIONAL SIGNATURE OF DIFFUSE LARGE B-CELL LYMPHOMAS ACCORDING TO THE PRIMARY ORGAN
por: Koh, Hyun Hee, et al.
Publicado: (2023)

PB2206: PROGRESSION FACTORS OF MYELOFIBROSIS BASED ON CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROMBOCYTHEMIA: A CHINES TWO-CENTER RETROSPECTIVE STUDY
por: Xiang, Danhong, et al.
Publicado: (2023)

PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF
por: Kuykendall, Andrew, et al.
Publicado: (2023)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS
por: Al-Ali, Haifa Kathrin, et al.
Publicado: (2023)

PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
por: Koster, K.-L., et al.
Publicado: (2022)

PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)
por: Mascarenhas, John, et al.
Publicado: (2023)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB1785: DISCOVERY OF APPROVED LOW-TOXICITY AGENTS DISRUPTING ACUTE MYELOID LEUKEMIA STEM AND PROGENITOR CELLS
por: Meilstrup, J., et al.
Publicado: (2022)

PB1783: IDENTIFICATION OF RAMAN SPECTROSCOPIC SIGNATURE OF IDH MUTATIONS IN AML IN VITRO MODEL
por: Laskowska, P., et al.
Publicado: (2022)

PB1768: MICRORNA SIGNATURES IMPLY A ROLE FOR FOXO IN AML CHEMO-RESISTANCE
por: Reichelt, Paula, et al.
Publicado: (2023)

PB2487: SECONDARY HLH: RETROSPECTIVE DATA FROM TERTIARY CARE CENTRE.
por: Wasekar, Nilesh, et al.
Publicado: (2023)

PB2061: A NEW DIAGNOSTIC TOOL BASED ON MOLECULAR APPROACHES APPLICABLE TO ROUTINE CLINICAL USE FOR FANCONI ANEMIA PATIENTS ORIGINATING FROM NORTH AFRICA
por: Kraiem, Olfa, et al.
Publicado: (2023)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
por: Gavrilenko, Andrey, et al.
Publicado: (2023)

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Palandri, Francesca, et al.
Publicado: (2023)

PB2709: BURDEN OF SEVERE INFECTIONS IN PRIMARY IMMUNODEFICIENCY DISEASES
por: Aggarwal, Saurabh, et al.
Publicado: (2023)

PB1860: CLONALITY RELATEDNESS AND MOLECULAR CHARACTERISTICS OF RICHTER SYNDROME
por: Sha, Y., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6cue9gopls0dvk1enrukupsoij